Expertise
Bone Marrow Modes for Patient-relevant and Predictive Drug Testing for Blood Cancers
Bone Marrow Engineering
Author
CEO and co-founder of Humaniche / Group Leader @ETH Zürich at ETH Zürich - Humaniche
Zürich, Switzerland
Dilara Perver
CEO and co-founder of Humaniche / Group Leader @ETH Zürich
ETH Zürich - Humaniche
Zürich, Switzerland
44 profile visits
We develop patient-matched preclinical bone marrow models for blood cancer drug and therapy development to address high rates of late-stage drug attrition.
My organisation
Humaniche is an ETH Zürich spin-off in formation, developing a family of off-the-shelf and disease-specific human bone marrow niche proxy kits and in vitro systems that provide structured insights into efficacy and hematopoietic toxicity at the stage immediately prior to first-in-human trials, where development risk and capital exposure are highest. Until now, it has raised CHF 588K in non-dilutive funding. By introducing functional human bone marrow biology into late preclinical decision-making, Humaniche reduces costly late-stage clinical failures and supports the pharmaceutical industry’s transition toward validated New Approach Methodologies (NAMs). By developing human-relevant, scalable, and reproducible bone marrow disease model tools, Humanishe aims to enable safer, more effective advanced therapies to efficiently reach blood cancer patients.
About me
I am the co-founder of Humaniche, an ETH Zürich biotech spin-off in formation, developing predictive human bone marrow models as microenvironment-mimetic pre-clinical test platforms to improve decision-making in blood cancer drug development. Our systems enable more reliable evaluation of hematopoietic toxicity and efficacy for advanced therapies, including cell and gene therapies, ADCs, and targeted oncology drugs. My background combines biomedical engineering from ETH Zürich, clinical trial management training, and an MBA at the University of St. Gallen, supporting a strong focus on portfolio strategy, evidence generation, and commercialization of research technologies. I am particularly interested in collaborations with pharma, biotech, and CDMOs working on predictive preclinical systems, advanced therapy development, and next-generation testing approaches aligned with emerging regulatory expectations.